Human microbiota and effectiveness of cancer chemotherapy
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-2.14611Keywords:
cancer, chemotherapy, microbiota, tumor-microbiota relationshipsAbstract
Summary. This review presents up-to-date information on the effects of microbiota on the individual chemotherapy sensitivity in cancer treatment. Recent studies have shown that a fine balance between the intestinal microbiota and the immune system is crucial for maintaining an efficacy of cancer chemotherapy. A number of antitumor drugs have complex mechanisms of action involving not only direct effects but also the activity of the intestinal microbiota and the immune system. A unique combination of these factors contributes to the individual chemotherapy sensitivity.
References
Chen W, Wang S, Wu Y, et al. Immunogenic cell death: A link between gut microbiota and anticancer effects. Microb Pathog 2020; 141: 103983.
Simon JC, Marchesi JR, Mougel C, Selosse MA. Host-microbiota interactions: from holobiont theory to analysis. Microbiome 2019; 5: 1–5.
Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer 2017; 17: 271–87.
Adamczyk A, Westendorf AM. Cancer, drugs, and bugs — bacteriotherapy on the rise? J Leukoc Biol 2018; 103: 1–3.
Zou Y, Xue W, Luo G, et al. 1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses. Nat Biotechnol 2019; 37: 179–85.
Lloyd-Price J, Mahurkar A, Rahnavard G, et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature 2017; 550: 61–87.
Sender R, Fuchs S, Milo R. Are we really wastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 2016; 164: 337–40.
Sankar SA, Lagier JC, Pontarott P, et al. The human gut microbiome, a taxonomic conundrum. Syst Appl Microbiol 2015; 38: 276–86.
Deering KE, Devine A, O’Sullivan TA, Lo J, et al. Characterizing the composition of the pediatric gut microbiome: a systematic review. Nutrients 2020; 12: 1–24.
Blekhman R, Goodrich JK, Huang K, et al. Host genetic variation impacts microbiome composition across human body sites. Genome Biol 2015, 16: 191.
Hall AB, Tolonen AC, Xavie RJ. Human genetic variation and the gut microbiome in disease. Nat Rev Genet 2017; 18: 690–700.
Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 2019; 570: 462–7.
El Rakaiby M, Dutilh BE, Rizkallah MR, et al. Pharmacomicrobiomics: The impact of human microbiome variations on systems pharmacology and personalized therapeutics. OMICS 2014; 18: 1–13.
Nunes SC, Serpa J. Recycling the interspecific relations with epithelial cells: bacteria and cancer metabolic symbiosis. Adv Exp Med Biol 2020; 1219: 77–91.
O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7: 688–93.
Gori S, Inno A, Belluomini L, et al. Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. Crit Rev Oncol Hematol 2019; 143: 139–47.
Dzutsev A, Badger JH, Perez-Chanona E, et al. Microbes and Cancer. Annu Rev Immunol 2017; 35: 199–228.
Hong BY, Sobue T, Choquette L, et al. Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis. Microbiome 2019; 7: 1–18.
Campbell O, Gagnon J, Rubin JE. Antibacterial activity of chemotherapeutic drugs against Escherichia coli and Staphylococcus pseudintermedius. Lett Appl Microbiol 2019; 69: 353–7.
Domalaon R, Ammeter D, Brizuela M, et al. Repurposed antimicrobial combination therapy: tobramycin-ciprofloxacin hybrid augments activity of the anticancer drug mitomycin C against multidrug-resistant gram-negative bacteria. Front Microbiol 2019; 10: 1–9.
Flórez AB, Sierra M, Ruas-Madiedo P, Mayo B. Susceptibility of lactic acid bacteria, bifidobacteria and other bacteria of intestinal origin to chemotherapeutic agents. Int J Antimicrob Agents 2016; 48: 547–50.
Perales-Puchalt A, Sanz JP, Payne KK, et al. Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 2018; 103: 799–805.
Zhao L, Xing C, Sun W, et al. Lactobacillus supplementation prevents cisplatin-induced cardiotoxicity possibly by inflammation inhibition. Cancer Chemoth Pharm 2018; 82: 999–1008.
Xu X, Zhang X. Effects of cyclophosphamide on immune system and gut microbiotain mice. Microbiol Res 2015; 171: 97–106.
Zhou B, Xia X, Wang P, et al. Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota. EBioMedicine 2018; 33: 122–33.
Wu CH, Ko JL, Liao JM, et al. D-methionine alleviates cisplatin-induced mucositis by restoring the gut microbiota structure and improving intestinal inflammation. Ther Adv Med Oncol 2019; 11: 1–18.
Stringer AM, Gibson RJ, Logan RM, et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med 2009; 234: 430–41.
Wu R, Mei X, Wang J, et al. Zn(II)-Curcumin supplementation alleviates gut dysbiosis and zinc dyshomeostasis during doxorubicin-induced cardiotoxicity in rats. Food Func 2019; 10: 5587–604.
Chiba A, Bawaneh A, Velazquez C, et al. Neoadjuvant chemotherapy shifts breast tumor microbiota populations to regulate drug responsiveness and the development of metastasis. Mol Cancer Res 2019; 18: 130–9.
Groizeleau J, Rybtke M, Andersen JB, et al. The anti-cancerous drug doxorubicin decreases the c-di-GMP content in Pseudomonas aeruginosa but promotes biofilm formation. Microbiol 2016; 162: 1797–807.
Chua LL, Rajasuriar R, Lim YLM, et al. Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy. BMC Cancer 2020; 20: 1–11.
Meunier A, Nerich V, Fagnoni-Legat C, et al. Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs. J Antimicrob 2019; 74: 1572–7.
Papanicolas LE, Gordon DL, Wesselingh SL, Rogers GB. Not just antibiotics: Is cancer chemotherapy driving antimicrobial resistance? Trends Microbiol 2017; 26: 393–400.
Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastro Hepat 2017; 14: 356–66.
Nagpal R, Yadav H. Bacterial translocation from the gut to the distant organs: An overview. Ann Nutr Metab 2017; 71: 11–6.
Rigby RJ, Carrb J, Orgelc K, et al. Intestinal bacteria are necessary for doxorubicin-induced intestinal damage but not for doxorubicin-induced apoptosis. Gut Microbes 2016; 7: 414–24.
Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971–6.
Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis — current evidence and potential clinical applications. Aliment Pharmacol Ther 2014; 40: 409–21.
Druml W. Intestinal cross-talk: The gut as motor of multiple organ failure. Med Klin Intensiv Med Notes 2018; 113: 470–7.
Fukui H. Increased intestinal permeability and decreased barrier function: does it really influence the risk of inflammation? Inflamm Intest Dis 2016; 1: 135–45.
Carr JS, King S, Dekaney CM. Depletion of enteric bacteria diminishes leukocyte infiltration following doxorubicin induced small intestinal damage in mice. PLoS One 2017; 12: 1–16.
Yang J, Liu KХ, Qu JМ, Wang XD. The changes induced by cyclophosphamide in intestinal barrier and microflora in mice. Eur J Pharmacol 2013; 714: 120–4.
Russo F, Linsalata M, Clemente C, et al. The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. BMC Cancer 2013; 13: 1–11.
Messaritakis I, Vogiatzoglou K, Tsantaki K, et al. The prognostic value of the detection of microbial translocation in the blood of colorectal cancer patient. Cancers 2020; 12: 1–14.
Hughes E, Scurr M, Campbell E, et al. T-cell modulation by cyclophosphamide for tumour therapy. Immunology 2018; 154: 62–8.
Daillère R, Vétizou M, Waldschmitt N, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 2016; 45: 931–43.
Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967–70.
Vétizou M, Waldschmitt N, Kroemer G, et al. Fine-tuning cancer immunotherapy: optimizing the gut microbiome. Cancer Res 2016; 76: 4602–7.
Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 2018; 6: 1–13.
Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 2017; 357: 1156–60.
Yan A, Culp E, Perry J, et al. Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis 2018; 4: 68–76.
Villéger R, Lopès A, Carrier G, et al. Intestinal microbiota: A novel target to improve anti-tumor treatment? Int J Mol Sci 2019; 20: 1–25.
Wu J, Li Q, Fu X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity. Transl Oncol 2019; 12: 846–51.
Zhang S, Yang Y, Weng W, et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res 2019; 38: 1–13.
Boursi B, Mamtani R, Haynes K, Yang YX. Recurrent antibiotic exposure may promote cancer formation — another step in understanding the role of the human microbiota? Eur J Cancer, 2015, 51: 2655–64.
Pflug N, Kluth S, Vehreschild JJ, et al. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology 2016; 5: e1150399.
Gui QF, Lu H-F, Zhang CX, et al. Well-balanced commensal microbiota contributes o anti-cancer response in a lung cancer mouse model. Genet Mol Res 2015; 14: 5642–51.
Nenclares P, Bhide SA, Sandoval-Insausti H, et al. Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy. Eur J Cancer 2020; 131: 9–15.
van Vliet MJ, Tissing WJ, Dun CA, et al. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis 2009; 49: 62–70.
Huang K, Liu Y, Tang H, et al. Glabridin prevents doxorubicin-induced cardiotoxicity through gut microbiota modulation and colonic macrophage polarization in mice. Front Pharmacol 2019; 10: 1–15.
Xie JH, Fan ST, Nie SP, et al. Lactobacillus plantarum NCU116 attenuates cyclophosphamide-induced intestinal mucosal injury, metabolism and intestinal microbiota disorders in mice. Food Funct 2016; 7: 1584–92.
Jiang C, Wang H, Xia C, et al. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. Cancer 2019, 125: 1081–90.
Ding Y, Yan Y, Chen D, et al. Modulating effects of polysaccharides from the fruits of Lycium barbarum on the immune response and gut microbiota in cyclophosphamide-treated mice. Food Funct 2019; 10: 3671–83.
Tang Q, Zuo T, Lu S, et al. Dietary squid ink polysaccharides ameliorated the intestinal microflora dysfunction in mice undergoing chemotherapy. Food Funct 2014; 5: 2529–35.
Lérias JR, Paraschoudi G, de Sousa E, et al. Microbes as master immunomodulators: immunopathology, cancer and personalized immunotherapies. Front Cell Devl Biol 2020; 7: 1–17.
Bairi KE, Jabi R, Trapani D, et al. Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. Exp Rev Clin Pharmacol 2020: 1–19.
Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174–80.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
